Hydroxychloroquine
In the primary modified full analysis set, 18 of 36 hydroxychloroquine-treated participants developed rheumatoid arthritis during 24 months. Hydroxychloroquine served as the active comparator in the PALABA trial. Hydroxychloroquine was con…
1 sources - 5 claims
In the primary modified full analysis set, 18 of 36 hydroxychloroquine-treated participants developed rheumatoid arthritis during 24 months. Hydroxychloroquine served as the active comparator in the PALABA trial. Hydroxychloroquine was considered a clinically relevant comparator despite reducing internal validity relative to placebo. Hydroxychloroquine was given at 5 mg/kg per day throughout the two-year trial.